Biocon:
Biocon Surges After U.S. FDA Approval For Pegfilgrastim Drug From New UnitShares of Biocon Ltd. rose as much as 5.50 percent to Rs 278.50 apiece, the highest since Jun. 4, 2019.
The United States Food and Drug Administration, or U.S. FDA, has approved Biocon and Mylan's supplemental biologics licence application, or sBLA, for Pegfilgrastim drug to be manufactured at Biocon's new biologics facility in Bengaluru, the drugmaker said in an exchange filing on Wednesday.
This helps address growing U.S. market opportunities, Biocon said.
View: Positive in long run as well this was much awaited approval for Biocon.
News and major move played out today but Charts showed a rally coming on Monday itself.
Already booked 75% near T2 holding balance with Trail.